Trending: GSK Signs $3 Billion Shingles Vaccine Deal in China
Provided by
Dow Jones
1008 GMT - GSK has been among the most mentioned companies across news items over the past four hours, according to Factiva data. Shares of the British pharmaceutical giant rose 0.9% after it said it agreed on a deal valued at 2.5 billion pounds ($3.06 billion) with Chongqing Zhifei Biological Products for the exclusive distribution of its shingles vaccine in China. The three-year deal will start from Jan. 1 and has the option to be further extended. Dow Jones & Co. owns Factiva. (michael.susin@wsj.com)
(END) Dow Jones Newswires
October 09, 2023 06:23 ET (10:23 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back